o(6)-benzylguanine has been researched along with Melanoma in 8 studies
O(6)-benzylguanine: a suicide inhibitor of O(6)-methylguanine-DNA methyltransferase activity
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) induces DNA damage via a chloroethyl adduct at the O(6) position of guanine, which can be repaired by O(6)-alkylguanine DNA alkyltransferase (AGT) expressed in melanoma." | 9.11 | Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. ( Dolan, E; Gajewski, TF; Gerson, SL; Lin, S; Liu, L; Sosman, J; Vokes, EE, 2005) |
| " Aim of the present study was to investigate the molecular mechanisms underlying acquired resistance of melanoma cells to TMZ and the effect of O6-benzylguanine (BG), a specific MGMT inhibitor, on the development of a TMZ-resistant phenotype." | 7.73 | A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system. ( Alvino, E; Bonmassar, E; Caporali, S; Caporaso, P; Castiglia, D; D'Atri, S; Fischer, F; Jiricny, J; Lacal, PM; Marra, G; Pepponi, R; Zambruno, G, 2006) |
| "Fotemustine is a third generation chloroethylnitrosourea that has demonstrated significant antitumoral effects in malignant melanoma." | 7.72 | Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression. ( Cupissol, D; Cuq, P; Depeille, P; Evrard, A; Montero, JL; Passagne, I; Vian, L; Winum, JY, 2003) |
| "1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) induces DNA damage via a chloroethyl adduct at the O(6) position of guanine, which can be repaired by O(6)-alkylguanine DNA alkyltransferase (AGT) expressed in melanoma." | 5.11 | Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. ( Dolan, E; Gajewski, TF; Gerson, SL; Lin, S; Liu, L; Sosman, J; Vokes, EE, 2005) |
| " Aim of the present study was to investigate the molecular mechanisms underlying acquired resistance of melanoma cells to TMZ and the effect of O6-benzylguanine (BG), a specific MGMT inhibitor, on the development of a TMZ-resistant phenotype." | 3.73 | A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system. ( Alvino, E; Bonmassar, E; Caporali, S; Caporaso, P; Castiglia, D; D'Atri, S; Fischer, F; Jiricny, J; Lacal, PM; Marra, G; Pepponi, R; Zambruno, G, 2006) |
| "Fotemustine is a third generation chloroethylnitrosourea that has demonstrated significant antitumoral effects in malignant melanoma." | 3.72 | Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression. ( Cupissol, D; Cuq, P; Depeille, P; Evrard, A; Montero, JL; Passagne, I; Vian, L; Winum, JY, 2003) |
| " In melanoma specimens taken from a patient 3 h post-treatment with temozolomide, MGMT levels were reduced by 70%." | 3.69 | Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase. ( Alas, LG; Belanich, M; Citron, ML; Dolan, ME; Gander, M; Kibitel, JT; Lejeune, FJ; Li, BF; Pastor, MA; Randall, T; Schold, SC; Wasserman, P; White, AB; Yarosh, DB, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| von Felbert, V | 1 |
| Bauerschlag, D | 1 |
| Maass, N | 1 |
| Bräutigam, K | 1 |
| Meinhold-Heerlein, I | 1 |
| Woitok, M | 1 |
| Barth, S | 1 |
| Hussain, AF | 1 |
| Passagne, I | 1 |
| Evrard, A | 1 |
| Winum, JY | 1 |
| Depeille, P | 1 |
| Cuq, P | 1 |
| Montero, JL | 1 |
| Cupissol, D | 1 |
| Vian, L | 1 |
| Gajewski, TF | 1 |
| Sosman, J | 1 |
| Gerson, SL | 1 |
| Liu, L | 1 |
| Dolan, E | 1 |
| Lin, S | 1 |
| Vokes, EE | 1 |
| Alvino, E | 1 |
| Castiglia, D | 1 |
| Caporali, S | 1 |
| Pepponi, R | 1 |
| Caporaso, P | 1 |
| Lacal, PM | 1 |
| Marra, G | 1 |
| Fischer, F | 1 |
| Zambruno, G | 1 |
| Bonmassar, E | 1 |
| Jiricny, J | 1 |
| D'Atri, S | 1 |
| Fontijn, D | 1 |
| Adema, AD | 1 |
| Bhakat, KK | 1 |
| Pinedo, HM | 1 |
| Peters, GJ | 1 |
| Boven, E | 1 |
| Belanich, M | 1 |
| Randall, T | 1 |
| Pastor, MA | 1 |
| Kibitel, JT | 1 |
| Alas, LG | 1 |
| Dolan, ME | 1 |
| Schold, SC | 1 |
| Gander, M | 1 |
| Lejeune, FJ | 1 |
| Li, BF | 1 |
| White, AB | 1 |
| Wasserman, P | 1 |
| Citron, ML | 1 |
| Yarosh, DB | 1 |
| Middleton, MR | 1 |
| Kelly, J | 1 |
| Thatcher, N | 1 |
| Donnelly, DJ | 1 |
| McElhinney, RS | 1 |
| McMurry, TB | 1 |
| McCormick, JE | 1 |
| Margison, GP | 1 |
| Christmann, M | 1 |
| Pick, M | 1 |
| Lage, H | 1 |
| Schadendorf, D | 1 |
| Kaina, B | 1 |
1 trial available for o(6)-benzylguanine and Melanoma
| Article | Year |
|---|---|
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopla | 2005 |
7 other studies available for o(6)-benzylguanine and Melanoma
| Article | Year |
|---|---|
A specific photoimmunotheranostics agent to detect and eliminate skin cancer cells expressing EGFR.
Topics: Carcinoma, Squamous Cell; ErbB Receptors; Flow Cytometry; Fluorescent Dyes; Guanine; Humans; Immunot | 2016 |
Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression.
Topics: Antineoplastic Agents; Apoptosis; Carmustine; DNA Damage; Enzyme Inhibitors; Enzyme-Linked Immunosor | 2003 |
A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
Topics: Antineoplastic Agents; Base Pair Mismatch; Dacarbazine; DNA Methylation; DNA Repair; Drug Resistance | 2006 |
O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Blotting, Western; Dac | 2007 |
Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase.
Topics: Animals; Cell Compartmentation; Cell Nucleus; Cytoplasm; Dacarbazine; DNA Repair; Enzyme Inhibitors; | 1996 |
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2000 |
Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT.
Topics: Antineoplastic Agents; Azacitidine; Blotting, Southern; DNA Methylation; DNA Repair; Drug Resistance | 2001 |